---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-033281"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2024-07-29T23:59:59+00:00"
generated_at: "2026-05-31T15:37:42.224099+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Corcept Q2 revenue up 39% to $163.8M; raises 2024 guidance to $640-670M

## Summary
- Q2 revenue $163.8M, up 39% YoY; diluted EPS $0.32 vs $0.25.
- 2024 revenue guidance raised to $640-670M from $620-650M.
- Cash and investments $492.5M at June 30, up from $451M at March 31.
- NDA submission for relacorilant in Cushing's syndrome expected Q4; late-stage trial results (ROSELLA, GRADIENT, DAZALS) due by year-end.
- Record number of new Korlym prescribers and patients; hypercortisolism screening expanding.

## SEC filing metadata
- accession: 0001628280-24-033281
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2024-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000162828024033281/0001628280-24-033281-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000162828024033281/cort-20240729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-033281
- JSON: https://secwatch.observer/filing/0001628280-24-033281.json
- Plain text: https://secwatch.observer/filing/0001628280-24-033281.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.